Table 2 Medical profiles and heights of the CAH participants
From: Health-related quality of life of female patients with congenital adrenal hyperplasia in Malaysia
Variables | CAH participants | |||||||
|---|---|---|---|---|---|---|---|---|
Age group I 10–12 years (n = 12) | Age group II 13–17 years (n = 29) | Age group III ≥ 18 years (n = 18) | Total N = 59 | |||||
f | % | f | % | f | % | f | % | |
CAH variants | ||||||||
 SW-CAH | 7 | 58.3 | 18 | 62.1 | 15 | 83.3 | 40 | 67.8 |
 SV-CAH | 5 | 41.7 | 11 | 37.9 | 2 | 11.1 | 18 | 30.5 |
 NC-CAH | 0 | – | 0 | – | 1 | 5.6 | 1 | 1.7 |
Daily corticosteroid replacement | ||||||||
 Prednisolone | 4 | 33.3 | 17 | 58.6 | 13 | 72.2 | 34 | 57.6 |
 Hydrocortisone | 8 | 66.7 | 12 | 41.4 | 5 | 27.8 | 25 | 42.2 |
On mineralocorticoids | 10 | 83.3 | 23 | 79.3 | 17 | 94.4 | 50 | 84.7 |
Hypertensive | 0 | 0 | 3 | 10.3 | 3 | 16.7 | 6 | 10.2 |
Participants’ perceived compliance to medications | ||||||||
 Excellent | 3 | 25.0 | 11 | 37.9 | 6 | 33.3 | 30 | 33.9 |
 Intermediate | 8 | 66.7 | 13 | 44.8 | 8 | 44.4 | 29 | 49.2 |
 Poor | 1 | 8.3 | 5 | 17.2 | 4 | 22.2 | 10 | 16.9 |
Other co-morbidities | 1 | 8.3 | 9 | 31.0 | 7 | 38.9 | 17 | 28.8 |
Had precocious puberty | 6 | 50.0 | 12 | 41.4 | 3 | 16.7 | 21 | 35.6 |
Learning disability | 2 | 16.7 | 6 | 20.7 | 2 | 11.1 | 10 | 16.9 |
Affected sibling (s) | 5 | 41.7 | 15 | 51.7 | 8 | 44.4 | 28 | 47.5 |
Height (cm), Mean (SD) | 142.7 (9.0) | 151.0 (6.8) | 149.0 (5.6) | Â | Â | |||
Obese or overweight | 5 | 41.6 | 10 | 34.4 | 6 | 33.4 | 21 | 35.6 |